Recent Advances in Thyroid Carcinoma—2nd Edition

Dear Colleagues,

Thyroid cancer is indolent, and affects more women than all other endocrine malignancies combined. However, follicular-derived carcinoma was determined as high risk in the WHO classification of endocrine and neuroendocrine tumors (5th edition). It is important to differentiate low-risk neoplasms and low-risk carcinoma from high-risk thyroid carcinoma, because there are significant differences between the clinical treatment of these tumor entities. Thyroid fine-needle aspiration biopsy is likely to be the best method to confirm most of the malignancy pre-surgery. Molecular detection is also available for diagnosis, risk stratification, and targeted therapy pre- and post-surgery. The forthcoming Special Issue focuses on the advances in thyroid carcinoma, including the following topics:

    Risk factors for thyroid carcinoma.

    Markers and new genes associated with thyroid cancer.

    Morphological and genetic features of low-risk thyroid neoplasms, and low-grade and high-grade thyroid carcinoma.

    Treatment related to thyroid cancer, including follicular-derived and C-cell-derived carcinoma.

    Predictors of treatment responses.

    Therapies and precision therapies for thyroid cancer.

    Diagnostic tools: strengths and limitations.

    International variations in thyroid cancer diagnosis and treatment.

    Determining thyroid cancer risk by using tests for the general population.

    Mitigating risk of thyroid cancer surgically or medically.

Prof. Dr. Zhiyan Liu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• thyroid
• cytology
• pathology
• therapy
• radio-iodine resistance
• targeted therapy

• Recent Advances in Thyroid Carcinoma in Diagnostics (8 articles)